Zervimesine

Clinical data
Other names	CT-1812; CT1812
Drug class	Sigma-2 receptor antagonist
Identifiers
IUPAC name 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol
CAS Number	1802632-22-9
PubChem CID	118278088
ChemSpider	72379940
UNII	0661V34NTV
KEGG	D13086
ChEMBL	ChEMBL4846092
Chemical and physical data
Formula	C24H33NO4S
Molar mass	431.59 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
InChI InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3 Key:ISQAPFMBJFZOLG-UHFFFAOYSA-N

Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name;^[1] developmental code name CT-1812 or CT1812) is a sigma-2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications.^[2][3][4]

The sigma-2 receptor is a binding site for β-amyloid oligomers.^[4] Zervimesine has been found to diplace β-amyloid oligomers from the sigma-2 receptor in both preclinical and clinical studies.^[4] As of 2024, effectiveness data on zervimesine for treatment of Alzheimer's disease are still lacking.^[4]

Zervimesine is under development by Cognition Therapeutics.^[2] As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration. The drug was also being developed for treatment of other cognitive disorders, but development for this indication was discontinued.^[2]

See also

• Blarcamesine

References